{"slug":"melanotan-ii","title":"melanotan ii","body":"## Overview\nEvidence is being populated by Grok web search.","register":"standard","tags":[],"category":null,"style":{},"claims":[{"id":"c1","text":"2025 case report linking Melanotan II nasal spray use to oral mucosal malignant melanoma in a young female; highlights unlicensed status and need for awareness of serious side effects.","section":"what_is_known","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair"},{"id":"c2","text":"May 2026 listing of ongoing Phase 2 RCT (NCT07437560) testing MT-II safety and efficacy as add-on to phototherapy for vitiligo repigmentation.","section":"what_is_known","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair"},{"id":"c3","text":"2026 case report of multiple primary melanomas in situ associated with recent Melanotan (II) exposure along with other risk factors.","section":"what_is_known","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair"},{"id":"c4","text":"2026 case report documenting oral mucosal pigmentation changes following Melanotan II use, with follow-up observations on resolution after discontinuation.","section":"what_is_known","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair"}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40210573/","title":"Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?","quote":"The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. ... Histological analysis confirmed the diagnosis of a mucosal malignant melanoma.","summary":"2025 case report linking Melanotan II nasal spray use to oral mucosal malignant melanoma in a young female; highlights unlicensed status and need for awareness of serious side effects.","author":"","publisher":"","date":"","claim_ids":["c1"]},{"id":"s2","type":"clinical_trial","url":"https://www.trialx.com/clinical-trials/listings/337033/melanotan-ii-mt-ii-as/","title":"Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","quote":"This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo. ... Recruiting","summary":"May 2026 listing of ongoing Phase 2 RCT (NCT07437560) testing MT-II safety and efficacy as add-on to phototherapy for vitiligo repigmentation.","author":"","publisher":"","date":"","claim_ids":["c2"]},{"id":"s3","type":"medical","url":"https://www.sciencedirect.com/science/article/pii/S2352512626002766","title":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use","quote":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. ... Melanotan I primarily targets MC1R, whereas melanotan II is a nonselective agonist with broader systemic effects","summary":"2026 case report of multiple primary melanomas in situ associated with recent Melanotan (II) exposure along with other risk factors.","author":"","publisher":"","date":"","claim_ids":["c3"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41752902/","title":"Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report","quote":"This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect.","summary":"2026 case report documenting oral mucosal pigmentation changes following Melanotan II use, with follow-up observations on resolution after discontinuation.","author":"","publisher":"","date":"","claim_ids":["c4"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}